Mito now offers a coronary artery calcium scan without a referral. Here’s what it shows, what it costs and what a zero doesn't promise.

AbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the ...

Six of ten patients in a small trial improved by two or more steps on a severity scale after one treatment, though the data ...

Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...

Annovis Bio is using an AI tool to speed up its FDA filing for buntanetap, a drug aimed at Alzheimer’s and Parkinson’s.

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...

As peptides surge in popularity, better evidence and cleaner supply chains could help the field grow without leaving patients ...

Two Lilly candidates posted fresh data in type 2 diabetes, and how the numbers were counted matters as much as the numbers.

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Aging Research and Drug Discovery meeting opened with a pitch for prevention and a program building the endpoints the field needs.

Zsolt Farkas of Evolut on why today's longevity valuations only work if the winners spend the next decade buying everything ...

Amorepacific deal puts therapeutic target discovery to work on skin aging – and Junevity sees scope for an ‘Ozempic moment’.